2025-05-27 - Analysis Report
Okay, here's an analysis of RXRX (Recursion Pharmaceuticals Inc.) based on the data you provided, presented in a report format suitable for an English-speaking audience.

---

## RXRX (Recursion Pharmaceuticals Inc.) Stock Analysis

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover and develop novel therapeutics.

### 1. Performance Relative to S&P 500 (VOO)

**Key Numbers:**

*   RXRX Cumulative Return: -62.10%
*   VOO Cumulative Return: 12.31%
*   Relative Divergence:
    *   Current: -74.4
    *   Max: 37.8
    *   Min: -76.2
    *   Relative Divergence (Position within Range): 1.6

**Analysis:**

RXRX has significantly underperformed the S&P 500 (VOO) over the period covered. The current relative divergence of -74.4 indicates a substantial gap in performance. The relative divergence of 1.6 suggests that the current underperformance is near the lowest end of its historical range relative to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD      | Alpha    | Beta   | Cap (B) |
| ---------- | -------- | -------- | -------- | ------ | ------- |
| 2021-2023  | 5.0%     | 73.6%    | 1.0%     | -0.1   | 4.0     |
| 2022-2024  | 0.0%     | 73.6%    | -17.0%    | -0.1   | 2.8     |
| 2023-2025  | -11.0%    | 77.2%    | -38.0%    | -0.1   | 1.7     |

**Analysis:**

*   **CAGR:** Shows a declining annual growth rate over the three periods, with the most recent period showing negative growth.
*   **MDD:** The Maximum Drawdown is consistently high, indicating significant risk and volatility in the stock's price.
*   **Alpha:** Consistently negative Alpha indicates that the stock is underperforming relative to its benchmark.
*   **Beta:** Low Beta suggests that the stock has very low correlation with the overall market, meaning its movements are largely independent of the S&P 500.
*   **Cap (B):** The market capitalization has decreased from $4.0 billion to $1.7 billion, reflecting a significant loss in market value.

### 2. Recent Stock Price Movement

**Key Numbers:**

*   Current Price: \$4.08
*   Previous Close: \$4.145
*   Change: -1.57%
*   5-Day Moving Average: \$4.276
*   20-Day Moving Average: \$4.691
*   60-Day Moving Average: \$5.4429

**Analysis:**

The current price is below all three moving averages (5, 20, and 60-day), indicating a downtrend. The recent decrease of -1.57% suggests continued negative momentum.

### 3. Technical Indicators

**Key Numbers:**

*   Market Risk Indicator (MRI): 0.366 (Low Risk)
*   RSI: 36.84 (Approaching Oversold)
*   PPO: -0.55
*   Hybrid Signal: cash_70%_Sell 69.9% of holdings (3323 shares - Caution - MRI:0.37)
*   Recent (20-day) Relative Divergence Change: +0.1 (Short-term Increase)
*   Expected Return: -1478.0%

**Analysis:**

*   The MRI indicates low market risk currently.
*   The RSI is below 50, suggesting the stock is in a downtrend and approaching oversold conditions.
*   The PPO is negative, confirming the downward trend.
*   The hybrid signal indicates a caution signal with a recommendation to sell a significant portion of holdings. The MRI value in the signal (0.37) also reinforces the caution.
*   The short-term increase in relative divergence (+0.1) might suggest a potential short-term bounce, but it's minor.
*   The highly negative expected return suggests very poor long-term prospects relative to the S&P 500.

### 4. Recent News & Significant Events

**Summary of News:**

*   Recent business developments, regulatory changes, or market events are affecting RXRX.
*   Analysts are discussing RXRX's performance and outlook considering industry and economic factors.
*   The stock has shown notable volatility.
*   Market experts advise monitoring recent news and company announcements.

**Analysis:**

The news suggests that RXRX is experiencing significant events influencing its stock performance, and awareness of these events is crucial for investors.

### 5. Recent Earnings Analysis

**Earnings Data:**

| 날짜       | EPS   | 매출     |
| ---------- | ----- | -------- |
| 2025-05-05 | -0.50 | 0.01 B$  |
| 2024-11-06 | -0.34 | 0.03 B$  |
| 2024-08-08 | -0.40 | 0.01 B$  |
| 2024-05-09 | -0.39 | 0.01 B$  |
| 2025-05-05 | -0.39 | 0.01 B$  |

**Analysis:**

The EPS (Earnings Per Share) has been consistently negative, indicating losses. While revenue fluctuates, it remains relatively low. This consistent lack of profitability is concerning.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| ---------- | ---------- | ------------- |
| 2025-03-31 | \$0.01B    | -47.31%      |
| 2024-12-31 | \$0.00B    | -183.62%     |
| 2024-09-30 | \$0.03B    | 53.69%       |
| 2024-06-30 | \$0.01B    | 36.14%       |
| 2024-03-31 | \$0.01B    | 17.23%       |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
| ---------- | ---------- | --------- |
| 2025-03-31 | \$0.93B    | -21.68%   |
| 2024-12-31 | \$1.03B    | -17.29%   |
| 2024-09-30 | \$0.52B    | -18.27%   |
| 2024-06-30 | \$0.58B    | -16.69%   |
| 2024-03-31 | \$0.40B    | -22.78%   |

**Analysis:**

*   **Revenue:** Revenue is inconsistent and relatively low for a company of this size.
*   **Profit Margin:** Profit margins are highly variable, with significant losses in some quarters. The recent negative profit margins are concerning.
*   **Equity:** Equity has fluctuated but remains substantial.
*   **ROE:** Return on Equity is consistently negative, indicating that the company is not generating profits from its equity.

### 7. 종합적인 분석 (Overall Analysis)

**Summary:**

RXRX is currently underperforming significantly compared to the S&P 500. Its stock is in a downtrend, as reflected in its price being below key moving averages, negative PPO, and approaching oversold RSI. The recent news suggests the company is experiencing impactful events. Financial performance reveals consistently negative EPS and fluctuating but often low revenue and profit margins. The expected return is highly negative.

**Conclusion:**

Based on the data, RXRX presents a high-risk investment opportunity. The company's underperformance, negative profitability, and concerning technical indicators warrant caution. While the low MRI might suggest limited market risk, the company-specific risks appear significant. Investors should closely monitor news and company announcements, as advised by market experts. A significant turnaround is needed for a positive outlook.
